Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Eman03 who wrote (585)	3/20/1998 8:51:00 PM
From: Paul Barr	Respond to of 965

You are right, life for CNTO won't be easy, it will be REALLY easy. Roche has been duped by Agouron(AGPH) best selling AIDS drug and now CNTO with this great acquisition. Roche is probably the worst run pharmaceutical alive. Go CNTO!!!

To: Eman03 who wrote (585)	3/20/1998 9:09:00 PM
From: Robohogs	Read Replies (1) \| Respond to of 965

CNTO knew about the lawsuit when they made the purchase and even worked out a sharing agreement on legal bills. CNTO also has a put option to return the drug to Roche and gets damages if they lose the lawsuit. They knew what they were doing. Call them.

To: Eman03 who wrote (585)	3/21/1998 12:53:00 AM
From: FNS	Read Replies (1) \| Respond to of 965

Assuming the lawsuit had been initiated between Roche and Genentech before the sale and that Roche has a 60% stake in Genentech, wouldn't it make more sense for Roche to negotiate the sale of Retavase to Genentech??? Or are you implying a setup/legal blackball tactics? I have to believe that CNTO isn't this naive! I hope. The marketing capability for Retavase should complement ReoPro and provide CNTO with an existing sales distribution channel for new drugs; i.e., Avakine. FNS